PL3716998T3 - A1AT w celu zmniejszenia ryzyka wystąpienia ostrej choroby przeszczep przeciwko gospodarzowi po przeszczepie komórek krwiotwórczych - Google Patents

A1AT w celu zmniejszenia ryzyka wystąpienia ostrej choroby przeszczep przeciwko gospodarzowi po przeszczepie komórek krwiotwórczych

Info

Publication number
PL3716998T3
PL3716998T3 PL18821851.5T PL18821851T PL3716998T3 PL 3716998 T3 PL3716998 T3 PL 3716998T3 PL 18821851 T PL18821851 T PL 18821851T PL 3716998 T3 PL3716998 T3 PL 3716998T3
Authority
PL
Poland
Prior art keywords
a1at
onset
host disease
cell transplantation
versus host
Prior art date
Application number
PL18821851.5T
Other languages
English (en)
Inventor
Marc UKNIS
Christine VOIGT
Gautam BAHETI
John Roberts
Original Assignee
Csl Behring Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Behring Llc filed Critical Csl Behring Llc
Publication of PL3716998T3 publication Critical patent/PL3716998T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
PL18821851.5T 2017-12-01 2018-11-30 A1AT w celu zmniejszenia ryzyka wystąpienia ostrej choroby przeszczep przeciwko gospodarzowi po przeszczepie komórek krwiotwórczych PL3716998T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762593446P 2017-12-01 2017-12-01
US201862729376P 2018-09-10 2018-09-10
PCT/US2018/063179 WO2019108865A1 (en) 2017-12-01 2018-11-30 Methods for reducing risk of onset of acute graft versus host disease after hematopoeitic cell transplantation

Publications (1)

Publication Number Publication Date
PL3716998T3 true PL3716998T3 (pl) 2024-06-24

Family

ID=64734181

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18821851.5T PL3716998T3 (pl) 2017-12-01 2018-11-30 A1AT w celu zmniejszenia ryzyka wystąpienia ostrej choroby przeszczep przeciwko gospodarzowi po przeszczepie komórek krwiotwórczych

Country Status (13)

Country Link
US (2) US11857610B2 (pl)
EP (2) EP4321220B1 (pl)
JP (2) JP2021505545A (pl)
AU (1) AU2018374285B2 (pl)
DK (1) DK3716998T3 (pl)
ES (1) ES2975208T3 (pl)
FI (1) FI3716998T3 (pl)
HR (1) HRP20240475T8 (pl)
HU (1) HUE066011T2 (pl)
PL (1) PL3716998T3 (pl)
PT (1) PT3716998T (pl)
SI (1) SI3716998T1 (pl)
WO (1) WO2019108865A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021028927A1 (en) * 2019-08-15 2021-02-18 Kamada Ltd Combination of alpha-1-antitrypsin and steroids and uses therefor
EP4408175A4 (en) * 2021-10-01 2025-08-06 Univ Colorado Regents COMPOSITIONS AND METHODS FOR REDUCED TOXICITY IN TRANSPLANTATION USING JANUS KINASE (JAK) INHIBITORS

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090118162A1 (en) * 2005-06-07 2009-05-07 Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of graft rejection and promotion of graft survival
US8715649B2 (en) 2005-06-07 2014-05-06 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods of use for alpha-1 antitrypsin having no significant serine protease inhibitor activity
US9457070B2 (en) 2005-06-07 2016-10-04 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses of alpha 1-antitrypsin for early intervention in bone marrow transplantation and treatment of graft versus host disease
US20090105341A1 (en) * 2005-12-24 2009-04-23 Teagasc Dairy Products Research Centre Process for the production of trans-10, cis 12 octadecadienoic acid
US20090028832A1 (en) * 2006-08-10 2009-01-29 Chung Leland F Compositions and methods for targeted tumor therapy
US8927488B2 (en) * 2010-05-17 2015-01-06 Cebix, Inc. Pegylated C-peptide
JP6216921B2 (ja) * 2011-06-24 2017-11-01 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ アルファ−１抗トリプシン融合分子のための組成物、方法および使用
US10400029B2 (en) * 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
CA2839619C (en) 2011-06-28 2021-11-16 Inhibrx Llc Serpin fusion polypeptides and methods of use thereof
KR20140137347A (ko) 2012-01-10 2014-12-02 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도
CA2943938A1 (en) 2013-03-29 2014-10-02 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for preparing a subject for organ or non-organ implantation
EP3397274A1 (en) 2015-12-31 2018-11-07 The Regents of the University of Colorado, a body corporate Methods and uses for alpha-1 antitrypsin or recombinant forms thereof, on steroid-refractory graft versus host disease involving gastrointestinal complications

Also Published As

Publication number Publication date
HRP20240475T8 (hr) 2024-08-02
FI3716998T3 (fi) 2024-04-16
EP4321220A3 (en) 2024-03-20
ES2975208T3 (es) 2024-07-04
AU2018374285A1 (en) 2020-07-02
DK3716998T3 (da) 2024-04-02
HRP20240475T1 (hr) 2024-07-05
EP4321220A2 (en) 2024-02-14
US20210008182A1 (en) 2021-01-14
EP3716998B1 (en) 2024-01-10
AU2018374285B2 (en) 2024-06-27
WO2019108865A1 (en) 2019-06-06
JP2021505545A (ja) 2021-02-18
PT3716998T (pt) 2024-04-09
SI3716998T1 (sl) 2024-05-31
EP3716998A1 (en) 2020-10-07
JP2024001191A (ja) 2024-01-09
HUE066011T2 (hu) 2024-07-28
US11857610B2 (en) 2024-01-02
US20240238395A1 (en) 2024-07-18
EP4321220B1 (en) 2025-10-29

Similar Documents

Publication Publication Date Title
EP3352670B8 (en) Method and system for assessing healing of tissue
IL253945A0 (en) kdm1a inhibitors to treat the disease
EP3687546A4 (en) COMPOSITIONS AND METHODS FOR TREATING HEART DISEASE WITH REDIRECTED T-LYMPHOCYTE IMMUNOTHERAPIES
IL269096A (en) Treatment of glycogen storage disease 3
IL288409A (en) Methods for gender determination of avian embryos in unhatched eggs and means thereof
EP3123860A4 (en) Acellular collagenous tissue and processing method of artificial valve comprising acellular collagenous tissue
SMT202100373T1 (it) Metodi e composizioni per la stimolazione del sistema enteroendocrino intestinale per il trattamento di malattie o condizioni correlate allo stesso
IL259486A (en) Substances for the treatment of diseases associated with unwanted cell proliferation
IL281032A (en) PDE9 inhibitors for the treatment of sickle cell disease
GB201406840D0 (en) Morphogenetically active hydrogel for bioprinting of bioartificial tissue
EP3541395A4 (en) GLYCOGENOSIS TREATMENT METHODS
EP3389620A4 (en) Stem cell stimulating compositions and methods of treating melasma
IL261750A (en) A method for preventing graft-versus-host disease
EP3647784A4 (en) ISOLATION OF CELLS OF EPITHELIAL ORIGIN THAT CIRCULATE IN THE PERIPHERAL BLOOD
IL289849A (en) Means and methods for reducing the tumorigenicity of cancer stem cells
SI3716998T1 (sl) A1at za zmanjšanje tveganja zagona akutne bolezni presadka proti gostitelju po presaditvi hematopoetskih celic
GB2585538B (en) Human microphysiological cell system for liver disease
IL261767A (en) Methods for treating or preventing graft-versus-host disease
EP3146965A4 (en) Selective inhibitors interfering with fibroblast growth factor receptor and frs2 interaction for the prevention and treatment of cancer and other diseases
IL274747A (en) FXR agonists for the treatment of liver diseases
IL267231A (en) Methods of treating diseases associated with ilc2 cells
PL3600210T3 (pl) Układ do mechanicznej stymulacji tkanki
PL3377075T3 (pl) Kompozycja do leczenia nieswoistego zapalenia jelit
EP3854402C0 (en) TREATMENT OR PREVENTION OF GRAFT-VERSE-HOST DISEASE
ZA201903833B (en) Novel multitarget drug for treating diseases in mammals